1. Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase;ChemMedChem,2007
2. Jump up^ US patent 7514444, Honigberg L, Verner E, Pan Z,Inhibitors of Bruton’s Tyrosine Kinase”, pharmacyclics Inc 7 April 2009, issued 28 December 2006.
3. Ibrutinib: first global approval;Cameron;Drugs,2014
4. Targeted covalent drugs of the kinase family;Singh;Curr. Opin. Chem. Biol.,2010
5. United States Food and Drug Administration;FDA approves Imbruvica for rare blood cancer,2019